Compare Monolithic Power Systems Inc (MPWR) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Monolithic Power Systems Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Monolithic Power Systems Inc trades at $1,379.55 (market cap $65.28B), while State Street SPDR S&P Biotech ETF trades at $154.41. The key difference: Monolithic Power Systems Inc pays a 0.6% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals.
| MPWR | XBI | |
|---|---|---|
Market Cap | $65.28B | — |
Sector | Utilities | Broad Market / Factor |
52-Week High | $1.69K | $164.28 |
52-Week Low | $711.24 | $85.16 |
Enterprise Value | $63.94B | — |
Dividend Yield | 0.6% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Monolithic Power Systems (MPWR) trades at $1,328.80, up 1.28% on the day, with technical indicators showing a bearish trend despite recent earnings beats. The company reported strong profitability with a 22.98% net income margin and is set to announce Q2 2026 results on July 30, 2026. Analyst sentiment remains overwhelmingly positive with a consensus price target of $1,780, representing significant upside potential from current levels.
MPWR's outlook is supported by robust fundamentals and AI infrastructure demand, but high valuation multiples and ongoing legal investigations pose risks. The stock offers growth exposure to power management semiconductors, though investors should weigh premium pricing against execution consistency and market volatility.
XBI trades at $150.94, down 2.14% today, with technical indicators showing a bearish trend but oversold RSI suggesting potential near-term support. The ETF lacks traditional valuation metrics due to its structure, but recent news highlights strong biotech sector momentum, including a 17% monthly gain and robust M&A activity. Analyst coverage is limited to a single hold rating, reflecting cautious optimism amid sector volatility.
Outlook: Biotech sector tailwinds from M&A and AI-driven drug discovery offer upside, but high volatility and policy risks persist. Investors should weigh XBI's equal-weight exposure to small/mid-cap biotech against its elevated beta, with technical support near $149 critical for short-term direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Monolithic Power Systems Inc
Monolithic Power Systems, Inc. is a global leader in high-performance, analog, and mixed-signal semiconductors. The company specializes in power management solutions, providing integrated circuits (ICs) for a wide range of applications, including computing, automotive, industrial, and communications. MPWR's proprietary process technology is designed to deliver highly energy-efficient and compact power solutions, positioning the company as a key supplier for the next generation of electronic devices.
Read more on MPWR →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
